Havrix

Havrix is a hepatitis A vaccine that contains inactivated hepatitis A virus adsorbed onto aluminium hydroxide hydrate and produced on human diploid cells. It is supplied as an injectable preparation for intramuscular administration. The product is authorized in the European Union and is prescribed by healthcare professionals for active immunisation against hepatitis A infection. Havrix is classified as a prescription‑only vaccine (Rx) and is included in routine vaccination schedules.

Havrix is indicated for the prevention of hepatitis A infection in individuals who are at risk of exposure.

- Adults and adolescents 12 months and older who have not been previously immunised against hepatitis A. - Travelers to regions where hepatitis A is endemic or where outbreaks occur. - Persons with occupational exposure to hepatitis A virus, such as laboratory workers. - Individuals with chronic liver disease who require protection against hepatitis A. - Close contacts of patients with confirmed hepatitis A infection.

The safety profile of Havrix reflects the typical reactions observed with inactivated viral vaccines.

Common: - Mild pain, redness or swelling at the injection site. - Low‑grade fever. - Headache. - Fatigue or general feeling of being unwell.

Serious: - Allergic reactions such as urticaria, angioedema or anaphylaxis. - Neurologic events including Guillain‑Barré syndrome (very rare).

Healthcare providers should consider several precautionary factors before administering Havrix to ensure safe and effective immunisation.

- Known severe allergy to any component of the vaccine, including aluminium salts. - History of anaphylactic reaction to a previous dose of Havrix. - Acute moderate or severe illness at the time of vaccination. - Pregnancy status is unknown; vaccination should be based on risk‑benefit assessment. - Immunocompromised individuals may have a reduced antibody response. - Children under 12 months are not approved for this vaccine.

Havrix does not have extensive drug‑drug interaction data, but certain agents may influence its immunogenicity or safety.

Avoid: - Concurrent administration of other live vaccines (e.g., measles, mumps, rubella) in the same syringe or injection site. - Use of immunoglobulin products within 2 weeks before or after vaccination, which may interfere with antibody development.

Use with caution: - Immunosuppressive therapy (e.g., corticosteroids, chemotherapy) may reduce vaccine efficacy. - Antipyretics such as acetaminophen or ibuprofen can be taken to manage mild post‑vaccination symptoms, but routine prophylactic use may blunt the immune response. - Blood products or plasma containing hepatitis A antibodies administered shortly before or after vaccination.